Toxicities Associated With PD-1/PD-L1 Blockade

Area of Science:

• Oncology
• Immunology
• Pathology

Background:

• Immune checkpoint inhibitors (ICIs), especially PD-1/PD-L1 blockers, yield durable responses in diverse cancers.
• While generally safe, ICIs can trigger autoimmune-like toxicities affecting multiple organ systems.

Purpose of the Study:

• To review the mechanisms of immune-related adverse events (irAEs).
• To outline the clinical and pathological features of major toxicities from PD-1/PD-L1 blockade.
• To summarize current management strategies for irAEs.

Main Methods:

• Literature review of immune checkpoint inhibitor mechanisms.
• Analysis of clinical and pathological data on irAEs.
• Synthesis of management guidelines for irAEs.

Main Results:

• PD-1/PD-L1 blockade can lead to a wide range of irAEs.
• Understanding irAE mechanisms is crucial for effective management.
• Corticosteroids are a primary treatment for ICI-induced toxicities.

Conclusions:

• PD-1/PD-L1 inhibitors are effective cancer treatments but require careful monitoring for irAEs.
• Prompt recognition and management of irAEs are essential for patient safety.
• Immune suppression, particularly corticosteroids, is key in managing these toxicities.